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Abstract
Insulin/IGF-I signaling regulates the metabolism of most mammalian tissues including pancreatic islets. To dissect the
mechanisms linking insulin signaling with mitochondrial function, we first identified a mitochondria-tethering complex in b-
cells that included glucokinase (GK), and the pro-apoptotic protein, BADS. Mitochondria isolated from b-cells derived from b-
cell specific insulin receptor knockout (bIRKO) mice exhibited reduced BADS, GK and protein kinase A in the complex, and
attenuated function. Similar alterations were evident in islets from patients with type 2 diabetes. Decreased mitochondrial GK
activity in bIRKOs could be explained, in part, by reduced expression and altered phosphorylation of BADS. The elevated
phosphorylation of p70S6K and JNK1 was likely due to compensatory increase in IGF-1 receptor expression. Re-expression of
insulin receptors in bIRKO cells partially restored the stoichiometry of the complex and mitochondrial function. These data
indicate that insulin signaling regulates mitochondrial function and have implications for b-cell dysfunction in type 2 diabetes.
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Introduction
Insulin and insulin like growth factor I (IGF-I) play critical roles
in triggering pleiotropic actions including metabolism, prolifera-
tion and survival in most mammalian cells including the
pancreatic islets [1]. The two hormones bind to their cognate
receptors and activate Akt/protein kinase B via the phosphatidy-
linositol 3-kinase (PI3-K)-generated polyphospho-phosphatidyli-
nositol pathway to phosphorylate the protein BAD in the
regulation of apoptosis [2]. Indeed, we and several other
laboratories have used cell line, primary islet and genetically
engineered mouse models to demonstrate that insulin/IGF-I
signaling plays a critical role in the regulation of hormone
secretion, proliferation and survival of pancreatic b-cells (see
review [3]). Among the various models, it is notable that mice with
b-cell specific knockout of insulin receptors (bIRKO) and/or IGF-
1 receptors demonstrate reduced expression of the glucokinase
(GK) gene and blunted glucose-stimulated insulin secretion
[4,5,6,7]. bIRKO mice also display an age-dependent decrease
in islet mass, poor compensatory islet response to high fat-diet
induced islet growth and increased susceptibility to diabetes,
suggesting a role for insulin signaling in the regulation of b-cell
survival [8].
While the precise defect in b-cell growth and/or function that
triggers overt diabetes is not fully understood, mitochondrial
dysfunction in b-cells has been implicated as one factor that
impairs b-cell survival and function [9]. Mitochondria play a
major role in insulin secretion [10,11] and in b-cell apoptosis
[12,13] triggered by diverse internal or external cues ultimately
promoting cell death [14]. Indeed, islets from patients with type 2
diabetes exhibit low ATP content and a blunted glucose-
stimulated insulin secretion (GSIS) and increased mitochondrial
volume [9], together implicating a role for mitochondria in the
pathogenesis of b-cell dysfunction.
Growth factor-mediated pathways have been reported to
modulate mitochondrial function and regulate the activity of the
pro-apoptotic protein, BAD [15]. Interestingly, studies in hepato-
cytes and b-cells have shown the presence of a BAD/glucokinase
complex at the mitochondria suggesting a point of intersection for
processes that regulate glycolysis and apoptosis [16]. Further,
hyperglycemia has been reported to modulate the levels of GK
and alter its interactions with mitochondria leading to apoptosis of
b-cells [17,18]. Considering the critical role of glucokinase in
cellular metabolism and survival, and our previous observations of
reduced expression of GK in b-cells lacking insulin or IGF-1
receptors [5,19], we undertook the current study to explore
whether absence of insulin signaling in b-cells impacts mitochon-
drial function.
In this study, we report the presence of a BAD/GK complex at
the mitochondria in mouse and human b-cells. Furthermore, we
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provide evidence that lack of insulin receptors in b-cells impacts
localization of BADS, alters the stoichiometry of the BAD/GK
complex and modulates phosphorylation of BADS that together
contribute to defects in mitochondrial function.
Results
Identification of BAD/glucokinase complex in b-cell
mitochondria
To explore the presence of a putative BAD/GK complex in b
cells, we isolated mitochondria from b-cell lines, or islets derived
from control or bIRKO mice and from diabetic and non-diabetic
human subjects. Mitochondria were subjected to microcystin pull
down assays. Similar to descriptions of the mitochondrial complex
in hepatocytes [16], we detected five proteins: WAVE1 (a protein
kinase A scaffold protein), glucokinase (GK), protein kinase A
(PKA), protein phosphatase 1 (PP1), and the pro-apoptotic protein
BADS (Fig. 1A–C). All components of the BAD/GK complex
were identified in cultured b-cells and in mouse and human islets,
indicating that this complex is conserved across species. Evaluation
of the distribution of each component in cytosolic and mitochon-
drial fractions revealed that WAVE1 exists largely in the cytosol
and mitochondrial WAVE1 comprises a small proportion of
cellular WAVE protein (Fig. 1D). Interestingly, we observed robust
expression of glucokinase in mitochondrial fractions when equal
amounts of protein from mitochondria and cytososl were loaded
(Fig. 1D). However, it is likely that the amount of GK that resides
in the cytosol is greater than at the mitochondria (Fig. 1D). Among
the BAD isoforms [17], BADL largely localized to the cytosol while
BADS was identified in both cytosolic and mitochondrial fractions.
On the other hand, PKA and PP1 were detectable in both cytosol
and mitochondria (Fig. 1D).
Assessment of the effects of absence of insulin receptors or of
insulin resistance on the complex, revealed a significant reduction
in BADS in mitochondrial samples from b-cell lines or islets isolated
from bIRKOmice and in islets isolated from humans with diabetes
(75% of control, p,0.05) (Fig. 1A–C and Fig. S4). In mitochondria
from b-cell lines isolated from bIRKO mice, PKA was reduced
(12% of control, p,0.05) (Fig. 1A), and we also observed a trend
towards a decrease in GK protein (29% of control, p = 0.08) in the
mutants. Together, these data indicate that absence of insulin
signaling in b-cells (bIRKO) or the diabetic state in humans is
linked to reduced BADS in the mitochondrial complex.
BADS phosphorylation, p70S6K and JNK signaling
BADS, a pro-apoptotic protein belonging to the Bcl-2 family,
can be phosphorylated in response to growth factors at three sites,
Ser-112, Ser-136 or Ser-155 [20]. Kinases implicated in activating
serine phosphorylation on BAD, include Akt/protein kinase B,
p70S6K, PKA, Rsk, and PAK1 [20]. To investigate the role of
insulin versus IGF-I in mediating BADS phosphorylation in b-
cells, we stimulated b-cells with either hormone and examined
mitochondrial or cytosolic fractions. For all experiments, the
purity of the fractions was confirmed (Fig. S1).
bIRKO mitochondria exhibit decreased BADS but
increased Ser-112 and Ser-136 BADS. Consistent with
reduced BADS protein in the BAD/GK complex, BADS content
was reduced in mitochondria isolated from bIRKO cells (Fig. 2A).
Phosphorylation of BADS at Ser-112 was increased in bIRKO
mitochondria but was virtually undetectable in control cells.
Figure 1. Presence of BAD/GK complex in mitochondria. Upper panels: Western blotting of five components in the BAD/GK complex with the
indicated antibodies. Lower panels: Mean data after quantitation. Each component was normalized to PP1 and control samples were set to an
arbitrary level of 1. A, control (Con) and bIRKO b-cell lines. B, control and bIRKO islet cells. C, islet cells from controls or patients with type 2 diabetes.
Representative of 3–5 independent experiments. * p,0.05; ** p,0.001 versus Control. Open bar: controls; Shaded bar: bIRKO or type 2 diabetes b-
cells. WAVE1, A protein kinase A scaffold; GK, glucokinase; PP1, protein phosphotase 1; PKA, protein kinase A; BADS, BCL2-antagonist of cell death. D,
Western blotting of five components in BAD/GK complex in cytosolic and mitochondrial compartments fractionated from control (Con) or bIRKO (KO)
b-cell lines. Equal amount of proteins was loaded in each lane. Using total amount of protein loaded for the cytosol and mitochondria ,20% of total
cellular GK is associated with mitochondria. L and S denote the large and small isoforms of BAD respectively.
doi:10.1371/journal.pone.0007983.g001
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Furthermore insulin stimulation increased Ser-112 BADS in
bIRKO mitochondria (Fig. 2B), which likely reflects insulin
signaling via intact IGF-1 receptors ([21] and Fig. 2D).
Relative to total levels of BADS, basal levels of Ser-136
phosphorylation of BADS were also increased in bIRKO
mitochondria versus controls, and phosphorylation tended to
increase further with insulin treatment (Fig. 2C). Compared to
changes in Ser-112 phosphorylation, these changes were not as
dramatic (Fig. S2A, B). Given the low abundance of BADS in the
bIRKO mitochondria we conclude that the majority of the
remaining BADS was in the phosphorylated state. The phosphor-
ylation of BADS is unlikely to involve Akt since its activation is
extremely low in bIRKO cells (see below). On the contrary,
phosphorylation of BAD is likely due to enhanced IGF-I signaling
in bIRKO cells (see below) that potentially activates RSK1, which
in turn, has been reported to phosphorylate BADS at both Ser-112
and 136 [22]. In support of this hypothesis, and consistent with
enhanced IGF-I signaling in bIRKO cells, we observed increased
Ser-112 phosphorylation of BADS in bIRKO but not in control
cells following incubation with IGF-I (Fig. 2D).
bIRKO cytosol expresses increased BADS and decreased
Ser-112 BADS. To evaluate relative changes in cytosol versus
mitochondria, we next examined signaling events in cytosolic
fractions. In bIRKO cytosol, the pattern of BADS expression and
phosphorylation were different than that observed in
mitochondria. Thus, total BADS showed a trend towards an
increase but Ser-112 phosphorylation was reduced in basal
conditions (Fig. 2E,F,G). The mitochondrial and cytosolic data
collectively suggest that BADS is redistributed away from the
mitochondria in the cytosol in bIRKO cells without a change in
the total cellular content of BADS. This was confirmed following
analysis of whole cell lysates showing no differences in total BADS
between bIRKO and control cells (Fig. 2H and Fig. S2A).
Cytosolic BADS protein content tended to increase in insulin
Figure 2. Altered expression of BADS and phospho-BADS in mitochondria and cytosol. Control or bIRKO cells were treated with 100 nM of
either insulin or IGF-I for 15 min and fractionated mitochondria and cytosol were examined. Protein levels were assessed by densitometry. Controls
were set to an arbitrary evel of 1. In Figures A though G, the upper panels show representative Western blots and lower panels show
mean values after quantitation of data. In H a representative Western blot is shown. Figures A, B, C and D relate to alterations in
isolated mitochondrial fractions and Figures E, F, and G relate to alterations in cytosolic fractions. A, Reduced total BADS, * p,0.05 bIRKO vs control
cells. B, Mitochondrial BADs phosphorylation at Ser-112, * p#0.05, basal vs insulin stimulation, n = 3. ND, non-detectable. C, Mitochondrial BADs
phosphorylation at Ser-136, * p#0.05, basal vs insulin stimulation, n = 3. D, Mitochondrial BADs phosphorylation at Ser-112 and Ser-136 under basal
or IGF-I stimulated conditions, * p#0.05 vs. Control basal; # p,0.05, bIRKO6IGF-I; n = 3. Open bar: controls; Shaded bar: bIRKO. E, Total cytosolic
BADS, * p,0.05. F and G, Ser-112 phosphorylation pattern of cytosolic BADS upon insulin (F) or IGF-I (G) treatments. * p,0.05 control basal vs bIRKO
basal; # p,0.05, control6insulin/IGF-I. H, Total BAD in whole cell lysates. Open bar: controls; Shaded bar: bIRKO.
doi:10.1371/journal.pone.0007983.g002
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stimulated control cells, but did not change in bIRKO cells. One
possible explanation for these observations is that increased Akt
activation, in control relative to bIRKO cells results in increased
phosphorylation of BADS at Ser-136 leading to sequestration of
Ser-136 BADS with 14-3-3 proteins in the cytoplasm of controls
(Fig. S2A) [23]. Therefore, relative to bIRKO cells, there is more
cytosolic Ser-136 BADs in control cells, which is consistent with
increased Akt-mediated phosphorylation and cytosolic
sequestration in control cells.
In the cytosolic fractions extracted from control cells, we
observed a significant decrease in Ser-112 phosphorylation of
BADS in response to either insulin or IGF-I stimulation (Fig. 2F,G).
The mechanism for this attenuation is uncertain, but these
observations raise the possibility that Ser-112 phosphorylation
might be negatively regulated by insulin or IGF-I mediated
activation of Akt. bIRKO cytosol contains less Ser-112 BADS
compared to control (Fig. 2F,G), which may suggest that
phosphorylation of Ser-112 BADS, may preferentially occur at
the mitochondria (Fig. 2B and Fig. S2A). Indeed, Ser-112
phosphorylation of BADS in bIRKO cytosol did not increase
following insulin treatment. In contrast, IGF-I treatment increased
Ser-112 phosphorylation in bIRKO cells (Fig. 2D) (p,0.05),
suggesting that the IGF-I signaling module that activates BAD,
might be hyperactivated in bIRKO cells (Fig. 2F,G).
bIRKO cells show increased mitochondrial P70S6K and
JNK1 activation. We next explored potential mechanisms that
could account for the preferential increase in phosphorylation of
BAD in mitochondria of bIRKO mice. Consistent with the
existence of mitochondria-tethered p70S6K in Rat-1a cells [24],
we also detected this kinase in mitochondria in b-cells. Indeed,
similar to other insulin sensitive cells, insulin stimulation of control
cells increased phosphorylation of mitochondrial p70S6K (Fig. 3A).
bIRKO mitochondria exhibited higher basal activation of Thr-
389 p70S6K in the mitochondrial and cytosolic fractions, which
did not increase any further following insulin stimulation (Fig. 3A,
B). It is possible that this reflects the consequence of increased
basal IGF-I signaling, particularly at the level of the mitochondria,
acting via Akt-independent signaling pathways such as MAPK
[25], which we believe provides a potential explanation for the
elevated phosphorylation of Ser-112 and Ser-136 of BADS in
bIRKO mitochondria [24]. Indeed, in isolated mitochondria,
addition of IGF-I significantly increased Thr-389 phosphorylation
of p70S6K in the bIRKOs but had minimal effect in the controls
(Fig. 3C). In contrast, IGF-I did not further increase cytosolic Thr-
389 phosphorylation of p70S6K beyond the elevated basal levels
in bIRKO (Fig. 3D).
The JNK (c-Jun N-terminal kinase) pathway is activated by
diverse stressors and can influence multiple cellular processes.
Figure 3. Altered phospho-p70S6K and phospho-JNK1 activation in mitochondria. Control or bIRKO cells were treated with 100 nM of
either insulin or IGF-I for 15 min and fractionated cytosol and mitochondria were used for analyses. Controls were set to an arbitrary level of 1. In each
Figure, the upper panel shows the representative Western blot and lower panel shows the mean value after quantitation of data. A, Responses in
mitochondrial p70S6K to insulin treatment. * p,0.05; # p#0.05. B, Responses in cytosolic p70S6K to insulin treatment. * p = 0.06; # p= 0.078; C and
D, Responses in mitochondrial and cytosolic p70S6K to IGF-I treatment in control and bIRKO cells. * p,0.05; # p,0.05. E and F, Responses in
mitochondrial and cytosolic JNK1 to IGF-I treatment in control and bIRKO cells. # p,0.05. Open bar: controls; Shaded bar: bIRKO.
doi:10.1371/journal.pone.0007983.g003
b-Cell Mitochondrial Complex
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Because mitochondrial dysfunction could activate stress signaling
in b-cells, we investigated JNK activity in mitochondria. JNK1
phosphorylation and total JNK1 protein was increased in
mitochondria from bIRKO cells (Fig. 3E), which is consistent
with the report that JNK co-localizes with mitochondria through
its interacting protein [26]. The trend towards increased basal
JNK1 phosphorylation levels in mitochondria, but not in cytosolic
fractions, suggests that JNK1 activation might be linked to the
stress induced by dysfunctional mitochondria in bIRKO cells
(Fig. 3E,F). In control cells, IGF-I but not insulin, triggered
phosphorylation of JNK1 in both mitochondrial and cytosolic
fractions (Fig. 3E,F). Thus, the JNK/MAPK pathway is more
responsive to IGF-I than to insulin in b-cells as has been suggested
in other cell types [27]. The lack of a similar effect of IGF-I in
bIRKO cells could be due to high basal activation of JNK1 that
precludes further activation (Fig. 3E,F).
Given the role of the BAD/GK complex in the regulation of
glycolysis and apoptosis [16], and our observations of changes in
the BAD/GK complex in bIRKO mitochondria, we reasoned that
these changes could be associated with impaired mitochondrial
function in bIRKO cells.
Altered mitochondrial function in bIRKO b-cells and islets
Blunted glucose-stimulated mitochondrial membrane
potential response in bIRKO b-cells and islets. Mitochondria
respond to glucose stimulation in a dose-dependent manner
by altering their membrane potential and mitochondrial
metabolism, which plays a determinant role in glucose-
stimulated insulin secretion [28,29]. To assess the membrane
potential response in islets ex vivo, we performed experiments
in dispersed islet b-cells derived from control or bIRKO mice
using the mitochondrial dye (TMRE). b-cells isolated from
bIRKO islets exhibited significantly reduced membrane
potential response to glucose stimulation compared to controls
(Fig. 4A,B) and similar results were observed in bIRKO cell lines
(Fig. S3A).
Decreased mitochondrial GK activity in bIRKO b-
cells. Increased mitochondrial membrane potential results
from increased glycolysis and oxidative phosphorylation. We
hypothesized that altered mitochondrial glucokinase activity
contributes to the poor membrane potential response to glucose
stimulation. We therefore measured glucokinase activity in
mitochondria using the G6PDH-coupled enzyme assay. Freshly
purified mitochondria from control cells showed a time-dependent
increase in NADPH generation and glucokinase enzyme activity in
response to glucose stimulation while there was significantly less
NADPH generation in mitochondria from bIRKO cells
(Fig. 4C,D). NADPH generation was not observed following
treatment with the non-metabolized analogue, 2-deoxy glucose,
confirming specificity of the assay (data not shown). Thus,
decreased level of BADS in the BAD/GK complex potentially
leads to reduced mitochondrial GK activity in bIRKO cells,
consistent with the reports in hepatocytes [16].
Decreased mitochondrial number and increased
mitochondrial size in bIRKO b-cells. A potential cause of
the decreased mitochondrial membrane potential response to
glucose is altered mitochondrial mass [30]. Electron microscopy
revealed that mitochondria in bIRKOs were rounded (Fig. 4H,
arrows) and larger than those in control islet cells (Fig. 4F and H),
but the number of mitochondria was reduced (Fig. 4E). The
mitochondrial volume densities, however, were not different
between the groups (Fig. 4G). Mitotracker staining of bIRKO
cell lines revealed fluorescence consistent with no reduction in
mitochondrial mass (Fig. S3B).
Increased mitochondrial oxygen consumption but
decreased cellular ATP content in bIRKO b-cells. To
further explore mechanisms that contribute to the lower
mitochondrial membrane potential in the bIRKOs, we
measured oxygen consumption responses to treatment with
glucose or DNP (2,4-dinitrophenol). Surprisingly, both control
and bIRKO cells responded with a similar rise in oxygen
consumption to either stimulus (Fig. 5A, B). Despite similar
increases in oxygen consumption in glucose-stimulated control and
bIRKO cells, there was a dramatic reduction in ATP content in
glucose-stimulated bIRKO cells (Fig. 5C). The increase in oxygen
consumption, accompanied by reduced ATP generation, and a
blunted increase in membrane potential suggests that bIRKO
mitochondria are significantly uncoupled. UCP2 expression was
increased in bIRKO cells (Fig. 5E) and could represent one
mechanism for mitochondrial uncoupling in these cells, similar to
that observed in other models of type 2 diabetes [31]. Interestingly,
expression levels of PGC-1a in the bIRKO cells were markedly
increased, which likely represents a compensatory response to
dysfunctional mitochondria (Fig. 5D). Recent studies have shown
that PGC-1a and PGC-1b are transcriptional regulators of UCP2,
and that increased PGC-1a/b - mediated upregulation of UCP2
may contribute to b cell dysfunction [32,33].
Rescue of phenotype by re-expression of insulin
receptors in bIRKOs
To confirm that the defects in mitochondria in bIRKO b-cells
are due to disrupted insulin signaling, we re-expressed the
human insulin receptor-B isoform in bIRKO b-cells and
revaluated the mitochondrial BAD/GK complex and mito-
chondrial function. In bIRKO cells re-expressing insulin
receptors, Akt phosphorylation was restored to ,70% of control
levels (Fig. 6A) and the enhancedexpression of IGF-1 receptors
and phospho-p70S6K were normalized to control levels
(Fig. 6A,B). In microcystin pull-down assays, we observed a
near-complete restoration of BADS in the BAD/GK complex,
while PKA was significantly higher in the re-expressors
compared to bIRKO fractions (Fig. 6C). Mitochondrial Thr-
389 p70S6K and Ser-112 BAD phosphorylation were normal-
ized in the absence of equivalent changes in phosphorylated
JNK (Fig. 6D). However, the level of expression of GK in the
complex was not completely restored suggesting that re-
establishing insulin/Akt signaling only partially improves the
stoichiometry of the BAD/GK complex in bIRKO b-cells.
In keeping with normalization of signaling complexes, re-
expression of insulin receptors in bIRKOs increased oxygen
consumption rates even further following stimulation with glucose
or DNP (Fig. 5A,B). ATP levels and mitochondrial membrane
potential showed an increase in glucose-stimulated cells (Fig. 5C
and Fig. S3A) and expression levels of PGC-1a and UCP2 were
restored to control levels (Fig. 5D,E). Thus re-expression of insulin
receptors restored mitochondrial energetics in bIRKO cells in part
by increasing mitochondrial coupling.
Discussion
In this study we examined the significance of insulin signaling
on mitochondrial function in pancreatic b-cells. We report that
disruption of insulin signaling in b-cells alters the stoichiometry of
a mitochondrial BAD/GK complex, reduces GK activity and
promotes mitochondrial dysfunction. Re-expression of the insulin
receptor in b-cells that lack insulin receptors largely restores the
complex and improves mitochondrial function, highlighting a
significant role for insulin signaling in the maintenance of the
b-Cell Mitochondrial Complex
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BAD/GK complex and in the regulation of mitochondrial
function.
The identification of a BAD/GK complex in both mouse and
human b-cells in this study indicates conservation across species
and supports the concept of a potential functional link between
apoptosis and glycolysis at the mitochondria, which is similar to
observations in hepatocytes [16]. Indeed, the WAVE protein in
the complex has been suggested to anchor GK and BAD to the
mitochondria to efficiently co-ordinate spatial and temporal
aspects of glucose metabolism [34]. The alterations in the
expression of different components in the complex in mitochon-
dria from b-cells from bIRKO provide potential insights into the
altered function of b-cells and may explain some of the phenotypes
observed in bIRKO mice [4,6]. Similar to effects observed in
BAD-deficient hepatocytes, decreased BADS protein in the
bIRKO cells likely contributes to mitochondrial dysfunction and
b-cell dysfunction, which may contribute to the glucose intoler-
ance in both of these mutants [16,35]. The BAD/GK complex
was also disrupted in islets from humans with type 2 diabetes and
showed an interesting similarity with islets from bIRKO mice.
Thus it is possible that reduced BADS in the mitochondria may be
linked to the blunted glucose response and altered mitochondrial
ultra structure observed in islets isolated from patients with type 2
diabetes [9].
Our study provides evidence that altered insulin signaling is
associated with mitochondrial function in the b-cell, as has
recently been reported in cardiomyocytes [36]. The mechanism
for mitochondrial dysfunction in bIRKO cells is multifactorial and
includes reduced glucose-mediated augmentation in mitochondrial
membrane potential and reduced ATP levels that could be due
either to decreased synthesis or to increased consumption in order
to maintain the membrane potential. Of interest, mitochondrial
dysfunction occurs despite increased oxygen consumption. These
observations suggest that despite reduced glucokinase activity and
Figure 4. Altered mitochondrial function in bIRKO b-cells. A–B, Reduced mitochondrial membrane potential response to glucose stimulation
in bIRKO b-cells. A, dispersed islet b-cells from control or bIRKO mice were stained by TMRE and analyzed by confocal microscopy. B, Fluorescence
intensity in images was quantitated by NIH ImageJ. n = 3–5;# p,0.05, 5.5 mM vs 18 mM glucose. Open bar: controls; shaded bar: bIRKO b-cells. C–D,
Reduced mitochondrial glucokinase activity in bIRKO b-cells. Glucokinase activity in freshly purified mitochondria from either control or bIRKO cells is
plotted as absorbance of glucose-6-phosphate dehydrogenase-driven increase in NADPH fluorescence (C). The activity is illustrated by the rates
determined by measuring optical density changes over linear periods, between 5 and 20 minutes (D). Mean of three independent experiments is
shown. The activities of controls were set to an arbitrary level of 1. * p,0.05. E–G, Altered mitochondrial number and size. Quantitative analyses of
mitochondrial ultrastructrue in islet b-cells from control or bIRKO mice. Mitochondrial number (E), size (F), and volume density (G) were quantitated as
described in Methods, * p,0.05, n = 5. H, Representative transmission electron microscopy (TEM) micrographs of islet b-cells from control or bIRKO
mice. Arrowheads point mitochondria showing increased size in bIRKOs. n = 28–30 cells from 3–5 mice. Magnification bar: 2 mM
doi:10.1371/journal.pone.0007983.g004
b-Cell Mitochondrial Complex
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potentially reduced glucose delivery to bIRKO mitochondria they
are also uncoupled. One potential mechanism for mitochondrial
uncoupling is increased UCP2 expression, which may be driven by
increased expression of PGC-1a and b [32,33]. Moreover,
increased UCP2 expression has been implicated in limiting
stimulus-secretion coupling in b-cells in some animal models of
diabetes but not in others [31,37]. However, it is possible that this
increased UCP2 expression may not contribute directly to
mitochondrial dysfunction in bIRKO cells and it could be the
result of ROS overproduction in response to glucose stimulation
since it was found that deletion of insulin receptors in heart
increases their propensity to enhance ROS when exposed to fatty
acid substrates [36]. Also, DNP experiments suggest that the
capacity of the OXPHOS machinery may not be intrinsically
impaired in bIRKO cells; the improvement in oxygen consump-
tion that we see in bIRKO and the rescued cells might be due to
altered mitochondrial mass (Fig. S3B); that might increase total
mitochondrial respiration. Together, the mitochondrial defects in
bIRKO cells could be results of combined effects from reduced
GK activity, ROS production and altered UCP2 expression.
Finally, we also measured mitochondrial membrane potential
response to glucose stimulation, and bIRKO cells that re-
expressed the insulin receptors showed a trend towards improved
membrane potential response in response to glucose (Fig. S3A),
which is also consistent with the increased respiration. Although
our experiments have not definitively identified all mechanisms
that could account for mitochondrial dysfunction, our study clearly
shows that impaired insulin signaling in b-cells fundamentally
alters mitochondrial bioenergetics and function, which may
ultimately impair insulin secretion.
Consistent with the growth factor-induced phosphorylation and
translocation of BADS [20] we observed significant alterations in
mitochondria isolated from b-cells lacking the insulin receptor.
The high level of basal phosphorylation of Ser112-BAD and
Ser136-BAD in the bIRKOs likely reflects the effects of signaling
via the IGF-1 receptors. It is possible that the relative levels of
activation of insulin versus IGF-1 receptors determine the overall
phosphorylation state of BAD at the mitochondria, with Ser112
phosphorylation being specifically mediated by Akt-independent
pathways, and Ser136 phosphorylation being activated by both
Akt and non-Akt pathways [38].
Intact IGF-I signaling in bIRKO cells could mediate the
activation of RSK and MSK1 to phosphorylate BAD at Ser-112
[22]. The phosphorylation state of BADS has also been reported to
impact its binding with other proteins such as Bcl-XL [39].
Further, the silencing of all serine sites in the BAD3SA/3SA mouse
Figure 5. Re-expression of insulin receptors improved altered mitochondrial function in bIRKO b-cells. A, Basal and 25 mM glucose
stimulated oxygen consumption rates (OCR) in control, bIRKO or bIRKO cells re-expressing insulin receptors (bIRKO+hIRB) cells, * p,0.05, n = 6. B, OCR
response to 60 mM DNP (2,4-Dinitrophenol) in control, bIRKO or bIRKO+hIRB cells. OCRs were normalized by cell numbers in all assays, * p,0.05,
n = 22. C, Re-expression of insulin receptors recovered the reduction of ATP production in bIRKO cells in response to 25 mM glucose stimulation. After
starvation, control, bIRKO or bIRKO+hIRB cells were treated with 2 mM and 25 mM glucose in KRB buffer for 30 min, ATP was extracted and
measured, ** p,0.001, n = 3. D and E, Re-expression of insulin receptors reduced the PGC1a and UCP2 expression to control levels. Expression levels
of PGC1a (D) and UCP2 (E) were assessed in control, bIRKO or bIRKO+hIRB cells using real-time PCR. All cells grown in normal culture conditions;
mRNA was extracted and cDNA was synthesized for real-time PCR, * p,0.05, n = 3.
doi:10.1371/journal.pone.0007983.g005
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has been reported to reduce GK activity in hepatocytes while
disruption of Ser-155 down-regulates GK activity in islets
[16,35]. These studies suggest that phosphorylation of BADS
can modulate GK activity and impact apoptosis, likely by
disruption of protein interactions in the complex. Our data
suggest that the level of BADS phosphorylation correlates with
function. This is reflected by the finding that bIRKO cells exhibit
extremely high Ser112 phosphorylation in mitochondria (Fig. 2B
and Fig. S2B) and phosphorylation can potentially interrupt the
interaction between BADS and other proteins, including GK.
Furthermore, re-expression of insulin receptors reversed the
increase in Ser112 phosphorylation of BADS and increased the
content of total BADS in the complex. Together, these data
suggest the potential relevance of interactions between Ser112
phosphorylation and function of the complex. Based on the
report by Danial et al [16], restoration of BADS in the complex
would augment glucokinase function and mitochondrial metab-
olism. Additional studies such as mutagenesis of Ser112 of BADS
will be necessary to prove a direct role of this phosphorylation
event. In bIRKO mitochondria it is possible that phosphoryla-
tion at Ser-112 disrupts the residence of BADS in the
mitochondrial complex and alters glucokinase activity and
mitochondrial metabolism without affecting Ser-155-BAD (data
not shown). These observations are consistent with the altered
glucose sensing and altered apoptosis of b-cells in bIRKO mice
[4,5,6]. The ability to reverse basal Ser-112 phoshorylation and
restore BADS content to control levels by re-expressing the
insulin receptor in bIRKO cells further underscores the role of
insulin signaling in regulating the mitochondrial complex.
Another signaling pathway that could potentially influence the
stoichiometry of the BAD/GK complex is the elevated expression
of PTEN secondary to enhanced IGF-I signaling in bIKRO cells
[40,41]. Increased PIP2 could decrease the binding of PKA in the
VCA domain of the WAVE protein, which is known to anchor
GK and BAD to the mitochondria to efficiently coordinate spatial
and temporal aspects of glucose metabolism [34,42] and may
Figure 6. Normalization of signaling complexes after re-expression of insulin receptor B isoforms in bIRKO b-cells. A, Upper panel,
Protein profile after expression of insulin receptors in bIRKO cells was immunoblotted by antibodies as indicated. p-Akt of controls were set to an
arbitrary level of 1, * p,0.05, n = 3. Lower panel shows quantitation of p-Akt to total Akt. B, Upper panel, P70S6K and phosphor-P70S6K were
assessed in cytosolic fractions from control, bIRKO or bIRKO cells re-expressing insulin receptors (bIRKO+hIRB), p-P70S6K of controls were set to an
arbitrary level of 1, * p,0.05, n = 3. Lower panel shows quantitation of p-P70S6K to total p70S6K. C, Upper panel, microcystin pull down assays to
demonstrate the five protein components of BAD/GK complex in mitochondria isolated from control, bIRKO or bIRKO cells re-expressing insulin
receptors (bIRKO+hIRB), * p,0.05. Lower panel, each component was normalized to PP1 which was set to an arbitrary level of 1 for each cell type. D,
Mitochondrial fractions isolated from control, bIRKO or bIRKO cells re-expressing insulin receptors (bIRKO+hIRB) were used to evaluate
phosphorylation of JNK1, p70S6K, BADS. Arrow indicates total JNK1.
doi:10.1371/journal.pone.0007983.g006
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contribute to the partial normalization of PKA content upon re-
expressing the insulin receptor in bIRKO cells.
In the cytosol, the elevated p70S6K activation in bIRKO cells
could potentially serine-phosphorylate IRS1 and further dampen
insulin-stimulation of Akt in bIRKO cells [43] (Fig. 7), and
potentiate IGF-I mediated pathways in the mutant cells. Indeed,
activation of Akt/PKB has been reported to inhibit IGF-I
activation of MAPK and mTOR pathways via Raf1 kinase, while
adenoviral knockdown of Akt/PKB in INS-1 cells leads to
enhanced ERK1/ERK2 signaling that is independent of IGF-I
signaling [25].
We observed high levels of JNK1 activation in mitochondria but
not in cytosolic fractions in bIRKO b-cells, which is consistent
with the report that JNK1 activation is linked to dysfunctional
mitochondria [44]. The activation of JNK1 by IGF-I, but not by
insulin, in both cytosolic and mitochondrial fractions in control b-
cells, implicates a role for IGF-I in the stress signaling pathway and
is consistent with the potentiation of cytokine-mediated JNK
following long-term IGF-I treatment [45]. We suggest that JNK1
could potentially contribute to Ser-112 phosphorylation on BADS
to affect mitochondrial metabolism and function (Fig. 7). Our
observations are consistent with the notion that down-regulation of
Akt does not influence basal mitochondrial respiration [46]. It will
be useful to dissect further, how insulin and IGF-I signaling
pathways differentially modulate MAPK and mTOR target
proteins, such as p70S6K and JNK1, to regulate mitochondrial
function in b-cells. Further work is also necessary to explore
whether insulin/IGF-I signaling directly modulates PGC-1a to
affect mitochondrial biogenesis and function [47,48].
In summary, this study provides novel insights into the role of
insulin signaling in the regulation of the BAD/GK complex,
glycolytic enzyme activity and mitochondrial metabolism in
pancreatic b-cells. Ser112-BADS and its upstream kinases may
be potential targets for the maintenance of the BAD/GK complex
that is necessary for normal mitochondrial function and the
regulation of b-cell survival.
Materials and Methods
Animals and cell lines
Experiments were performed using the b-cell specific insulin
receptor knockout mice (bIRKO) and Lox/Lox littermates as
controls [6]. All mice were maintained at the Taconic Facility (NY)
or Brandeis University (Waltham, MA). All experiments were
performed in compliance with Joslin Diabetes Center and
Brandeis University Animal Care and Use Committee regulations.
The control and bIRKO b-cell lines were derived and maintained
as described previously [49].
Mouse and human pancreatic islets
Mouse islets were isolated and purified by collagenase digestion
as described previously [6]. Isolated islets were cultured in RPMI
media with 10% FBS and 5.5 mM glucose for 48 h before
experiments. Islets from controls and patients with type 2 diabetes
Figure 7. Schematic showing the impact of insulin/IGF-I signaling on b-cell mitochondrial metabolism and function. Impairment of
insulin signaling alters BAD/GK complex and reduces mitochondrial function by inhibiting mitochondrial GK activity. The compensatory increase in
IGF-I signaling can impact phosphorylation of mitochondrial BAD to influence glucokinase activity and the mitochondrial threshold to cell death cues;
it can also impact mitochondrial p70S6K to phosphorylate BADs. Mitochondrial dysfunction due to impaired insulin signaling can activate
mitochondrial JNK1, which can phosphorylate mitochondrial substrate, e.g. BADS, to influence mitochondrial function and sensitivity to stress-
induced cell death.
doi:10.1371/journal.pone.0007983.g007
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were obtained from ICR (Islet Cell Resources, CA) and cultured in
Miami medium #1 (Mediatech, NJ) [50].
Mitochondrial isolation
Mitochondria were isolated using conventional differential
centrifugation [16]. Briefly, cell lines or islets were homogenized
in mitochondrial lysis buffer (220 mM mannitol, 70 mM glucose,
10 mM HEPES, 1 mM EGTA, pH 7.4). Subsequently, the lysate
was centrifuged at 700 g to separate nuclear and cytosolic
fractions, the cytosolic fraction was further centrifuged at 7000 g
at 4uC to pellet mitochondria. The isolated mitochondria were
subjected either to microcystin capture assay (see below), Western
blotting or mitochondrial glucokinase activity assay. For mito-
chondrial glucokinase activity assays, the isolated mitochondria
were further purified through a 30%–70% percoll gradient by
centrifugation at 20,000 rpm in a Beckman SW41 rotor for
40 min. The mitochondrial layer in the gradient was removed and
washed twice and immediately used for activity assays.
Microcystin capture assay
Isolated mitochondria from each respective b-cell line or from
islets were solubilized in the lysis buffer containing 6 mM CHAPS,
150 mM NaCl, 0.01 M sodium phosphate (pH 7.2) and 2 mM
EDTA. Based on the specific high affinity of microcystin for
protein phosphatase 1 (PP1) (one of the components in the BAD/
GK complex), the solubilized mitochondria were incubated with
microcystin beads (Upstate, NY) overnight at 4uC to pull down the
BAD/GK complex. After incubation, the microcystin beads were
washed and boiled in protein sample buffer. The protein bound to
the microcystin beads were resolved by SDS-PAGE gels and
detected by Western blotting to identify the components
precipitated on the beads.
Western blotting
To evaluate the role of insulin or IGF-I signaling, cell lines were
incubated with 100 nM of either insulin or IGF-I for 15 min at
37uC. The 15 min time point was chosen based on pilot
experiments to induce signaling effects in mitochondria. Proteins
were extracted from cells or islets as previously described [51]. The
protein concentration of each sample was determined using a BCA
kit (Pierce Biotechnology, Holmdel, NJ). The extracted proteins
were resolved by SDS-PAGE, and the protein was transferred to
PVDF membrane (Millipore, MA). Western blotting results were
normalized to actin and quantitated by densitometry. Antibodies
to the following proteins were used: Phospho-BAD, BAD,
phospho-p70S6K, p70S6K, phospho-JNK1, JNK1 (Cell Signaling
Technology, Boston, MA), glucokinase and protein phosphotase 1
(PP1) (Santa Cruz Biotechnology, Santa Cruz, CA), PKA
(Pharmingen, San Jose, CA) and evaluated in cytosol and
mitochondrial fractions.
Glucose-stimulated mitochondrial membrane potential
response in b-cell lines and dispersed islet b-cells
b-cells were dispersed from islets of control or bIRKO mice as
previously described [52]. Dispersed islet cells were cultured in
RMPI medium with 10% FBS, antibiotics, 5.5 mM glucose on
microscope coverslips and allowed to recover for 48 h. The
dispersed islet cells were stained with insulin and glucagon
antibodies to confirm purity of b-cells. Cells were stained with
10 nM TMRE (Molecular probe, Carlsbad, CA) for 45 min prior
to glucose stimulation. Fluorescence intensity of cells was initially
recorded in the basal condition followed by stimulation with
18 mM glucose. The altered fluorescence of treated cells was
recorded under a confocal microscope (Zeiss, Germany) within
10 min. The fluorescence intensity in basal and treated conditions
was quantitated by NIH Image J software (n = 60 to 80 cells). The
mitochondrial membrane potential change was calculated by
averaging fluorescence intensities before and after stimulation.
Mitochondrial glucokinase activity
Mitochondrial glucokinase activity was measured using a
glucose-6-phosphate dehydrogenase (G6PDH)-coupled enzyme
assay [53]. The total NADPH generated reflects glucokinase
activity in mitochondria. Briefly, ,3 mg of isolated mitochondria
was resuspended in reaction buffer containing 50 mM triethanol-
amine hydrochloride, 20 mM MgCl2, 100 mM KCl, 1 mM
dithiothreitol, 0.1% bovine serum albumin, 10 mM ATP, 1 mM
NADP and 4 mg/ml glucose-6-phosphate dehydrogenase (Sigma,
St. Louis, MO). Then, 90 mM glucose was added to initiate the
reaction and monitored by absorbance at 340 nm for 20 min at
RT. In order to decrease NADPH background generated from
mitochondrial respiration, all reactions were performed in the
presence of mitochondrial respiration inhibitors (4 mM Rotenone,
100 nM Antimycin A and 2 mg/ml Oligomycin).
Electron microscopy and determination of mitochondrial
number, size and volume density
Islets were fixed with 2.5% glutaraldehyde at RT for 2 h. Ultra-
thin sections (,60 nm) were cut and stained with uranyl acetate
and lead citrate before being examined under JOEL Transmission
Electron Microscope (Tokyo, Japan). At least five islets were
chosen randomly from control or bIRKO mouse islets and ,4
randomly selected b-cells from each islet were photographed. At
least 15 islet b-cells were examined from control or bIRKO islets
for number and morphology of the mitochondria. Mitochondrial
volume density and number were analyzed by stereology in a
blinded fashion using the point counting method, as described
previously [54]. Five representative images were analyzed per
genotype, and four grids per image were analyzed. Average size of
the mitochondria was calculated by dividing mitochondrial
volume density by mitochondrial number.
Re-expression of insulin receptor in bIRKO cells
Retroviral-packaging (Phoenix cells carrying the retroviral
vector was kindly provided by C. R. Kahn, MD (Joslin Diabetes
Center, Boston, MA). The vector encoding human insulin
receptor B was obtained from I. Leibiger, Ph.D (Karolinska
Institute, Stockholm, Sweden). Briefly, empty vector or vector
expressing the insulin receptor was transfected using lipofectamine
(Invitrogen, Carlsbad, CA) in Ø cells. The day after transfection,
DMEM medium, supplemented with 10% fetal bovine serum
(FBS) and 50 mg/ml gentamicin (Gibco, Invitrogen, Carlsbad, CA)
was replaced. Supernatant was collected 48 h post-transfection
and subjected to ultracentrifugation using an SW-28 rotor at
20,000 rpm. The transparent pellet was resuspended in 500 ml
phosphate buffered saline (PBS, pH 7.4), aliquoted and stored at
280uC until further use. bIRKO cells were transfected with
retrovirus particles. Twenty four h after transfection, 400 mg/ml
hygromycin (Gibco, Invitrogen, Carlsbad, CA) was added to select
the cells in which the expression vector was successfully integrated.
Measurement of Mitochondrial Respiration
Oxygen consumption rates (OCR) were measured in whole cells
by using a fiber-optic oxygen sensing probe as previously described
[55] or the Seahorse XF24. Briefly, cells were suspended at a
concentration of 26106 cells/ml by a magnetic stirrer at 37uC in a
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volume of 1 ml of buffer TD (137 mM NaCl, 5 mM KCl, 0.7 mM
Na2HPO4, 25 mM Tris-Cl, pH 7.4) and transferred to the
oxygen chamber. Endogenous (basal) respiration was measured
for 1 min. Glucose (final concentration 25 mM) or the uncoupler
2,4-dinitrophenol (DNP) was injected into the chamber (83 mM
final), and stimulated rates of oxygen consumption were
determined. The Seahorse machine (Seahorse Bioscience, Bill-
erica, MA) was used to measure oxygen consumption rate in
adherent cells in situ without trypsinization.
ATP assay
Cells were seeded in 12-well plates and incubated for 36–48 h
before incubation for an additional 16 h with 2 mM glucose in
DMEM with 0.1% BSA, followed by 2 mM glucose in KRB
buffer for one h. The cells were then either incubated in KRB
buffer containing 2 mM glucose (basal concentration) or KRB
buffer containing 25 mM glucose (stimulatory concentration) for
30 min. ATP was then extracted with 0.5% TCA solution for
15 min at 4uC. An aliquot of the TCA extracted samples were
diluted 20X with 0.1 M Tris-HCl, pH 7.75 buffer just before ATP
measurement with the ENLITENH ATP Assay System Biolumi-
nescence Detection Kit (Promega, Madison, WI) according to the
manufacturer’s recommendation. Total protein concentration was
measured using the BCA protein Assay (Pierce, Rockford, IL), and
ATP generated was normalized to total protein.
Statistics
Data were analyzed by Student’s ‘t’ test or analyses of variance
(ANOVA) with post-hoc comparisons as appropriate. Unless
otherwise indicated all experiments were performed on at least
three independent occasions.
Supporting Information
Figure S1 Mitochondrial purity assay. Mitochondria were
isolated from b-cells as described in Materials and Methods. To
examine the purity of either the mitochondrial or cytosolic
fraction, a mitochondrial marker COX4 or a cytosolic marker
actin were immunoblotted for each fraction.
Found at: doi:10.1371/journal.pone.0007983.s001 (0.20 MB PPT)
Figure S2 Distribution of BAD and phospho-BADS in b cells.
Control or bIRKO cells were treated with 100 nM insulin for
15 min and fractionated, cytosol, mitochondria and total lysates
were examined. A, Ser136-BADS, Ser112-BADS and total BADS
were immunoblotted. Tubulin and COX4 were used as loading
control for cytosol and mitochondria respectively. B, Magnified
image for Ser112-BADS in cytosol, mitochondria and total cell
lysate. L and S denote the isoforms of BADS.
Found at: doi:10.1371/journal.pone.0007983.s002 (0.15 MB PPT)
Figure S3 Altered mitochondrial membrane potential and mass.
A. Control, bIRKO or bIRKO+hIRB (bIRKO cells re-expressing
insulin receptors) cells were treated with 16.7 mM glucose and
stained with TMRE. The mitochondrial membrane potential
change was calculated by averaging fluorescence intensities before
and after stimulation. *p,0.05, control vs. bIRKO; p=0.068,
bIRKO vs. bIRKO+hIRB; n= 4. B. Control, bIRKO or bIRKO
cells re-expressing insulin receptors (bIRKO+hIRB) cells were
stained by Mitotracker dye and analyzed by flow cytometry;
*p,0.05, control vs. bIRKO, and bIRKO vs. bIRKO+hIRB;
n= 3.
Found at: doi:10.1371/journal.pone.0007983.s003 (0.07 MB PPT)
Figure S4 Western immunoblotting of the five components in
BAD/GK complex in islets from patients with type 2 diabetes.
Islets from three controls and three patients with type 2 diabetes
were fractionated and mitochondrial fractions were assessed using
a mycrocystin pull-down assay. The pull-down was used to detect
the five components that constitute the BAD/GK complex, using
antibodies indicated in the figure and described in Methods.
Found at: doi:10.1371/journal.pone.0007983.s004 (0.43 MB PPT)
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